These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

81 related items for PubMed ID: 14586876

  • 1. Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejection.
    Kugelmas M, Osgood MJ, Trotter JF, Bak T, Wachs M, Forman L, Kam I, Everson GT.
    Liver Transpl; 2003 Nov; 9(11):1159-65. PubMed ID: 14586876
    [Abstract] [Full Text] [Related]

  • 2. Repeated steroid pulse therapies in HCV-positive liver recipients: significant risk factor for HCV-related graft loss.
    Bahra M, Neumann UP, Jacob D, Langrehr JM, Neuhaus P.
    Transplant Proc; 2005 May; 37(4):1700-2. PubMed ID: 15919436
    [Abstract] [Full Text] [Related]

  • 3. Hepatitis C virus viral load after conversion from tacrolimus to cyclosporine in liver transplant patients: a pilot study.
    Guitard J, Sandres-Sauné K, Kamar N, Ribes D, Faguer S, Esposito L, Lavit M, Muscari F, Péron JM, Lavayssière L, Durand D, Rostaing L.
    Transplant Proc; 2007 Oct; 39(8):2603-5. PubMed ID: 17954189
    [Abstract] [Full Text] [Related]

  • 4. A novel immunosuppressive strategy combined with preemptive antiviral therapy improves the eighteen-month mortality in HCV recipients transplanted with aged livers.
    Urbani L, Mazzoni A, Colombatto P, Bindi L, Biancofiore G, Tascini C, Menichetti F, Brunetto MR, Scatena F, Filipponi F.
    Transplantation; 2008 Dec 27; 86(12):1666-71. PubMed ID: 19104402
    [Abstract] [Full Text] [Related]

  • 5. Ribavirin dose modification based on renal function is necessary to reduce hemolysis in liver transplant patients with hepatitis C virus infection.
    Jain AB, Eghtesad B, Venkataramanan R, Fontes PA, Kashyap R, Dvorchik I, Shakil AO, Kingery L, Fung JJ.
    Liver Transpl; 2002 Nov 27; 8(11):1007-13. PubMed ID: 12424713
    [Abstract] [Full Text] [Related]

  • 6. Influence of immunosuppression and effect of hepatitis C virus on new onset of diabetes mellitus in liver transplant recipients.
    Sánchez-Pérez B, Aranda Narváez JM, Santoyo Santoyo J, Fernández-Aguilar JL, Suárez Muñoz MA, González-Sánchez AJ, Pérez Daga JA, Ramírez Plaza CP, Carrasco Campos J, Jiménez Mazure C, Becerra Ortíz R.
    Transplant Proc; 2008 Nov 27; 40(9):2994-6. PubMed ID: 19010171
    [Abstract] [Full Text] [Related]

  • 7. Effects of immunosuppressants on the progression of hepatitis C in hepatitis C virus-positive renal transplantation and the usefulness of interferon therapy.
    Nanmoku K, Imaizumi R, Tojimbara T, Nakajima I, Fuchinoue S, Sakamoto N, Watanabe M, Teraoka S.
    Transplant Proc; 2008 Sep 27; 40(7):2382-5. PubMed ID: 18790241
    [Abstract] [Full Text] [Related]

  • 8. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
    Abdelmalek MF, Firpi RJ, Soldevila-Pico C, Reed AI, Hemming AW, Liu C, Crawford JM, Davis GL, Nelson DR.
    Liver Transpl; 2004 Feb 27; 10(2):199-207. PubMed ID: 14762857
    [Abstract] [Full Text] [Related]

  • 9. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK, Bansal SB, Gupta A, Gulati S, Kumar A, Prasad N.
    Clin Transplant; 2006 Feb 27; 20(6):677-83. PubMed ID: 17100715
    [Abstract] [Full Text] [Related]

  • 10. Predictors of sustained virological response after antiviral treatment for hepatitis C recurrence following liver transplantation.
    Cescon M, Grazi GL, Cucchetti A, Vetrone G, Ravaioli M, Ercolani G, Morelli MC, Piscaglia F, Tamè M, Pinna AD.
    Liver Transpl; 2009 Jul 27; 15(7):782-9. PubMed ID: 19562715
    [Abstract] [Full Text] [Related]

  • 11. Effect of long-term tacrolimus immunosuppression on renal function in liver transplant recipients.
    Corman SL, Coley KC, Schonder KS.
    Pharmacotherapy; 2006 Oct 27; 26(10):1433-7. PubMed ID: 16999653
    [Abstract] [Full Text] [Related]

  • 12. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus.
    Levy G, Grazi GL, Sanjuan F, Wu Y, Mühlbacher F, Samuel D, Friman S, Jones R, Cantisani G, Villamil F, Cillo U, Clavien PA, Klintmalm G, Otto G, Pollard S, McCormick PA.
    Liver Transpl; 2006 Oct 27; 12(10):1464-72. PubMed ID: 17004259
    [Abstract] [Full Text] [Related]

  • 13. Survival and hepatitis C virus recurrence after liver transplantation in HIV- and hepatitis C virus-coinfected patients: experience in a single center.
    Testillano M, Fernandez JR, Suarez MJ, Gastaca M, Bustamante J, Pijoan JI, Montejo M, Valdivieso A, Ruiz P, Gonzalez J, Ortiz de Urbina J.
    Transplant Proc; 2009 Apr 27; 41(3):1041-3. PubMed ID: 19376421
    [Abstract] [Full Text] [Related]

  • 14. Optimizing tacrolimus therapy in the maintenance of renal allografts: 12-month results.
    Bolin P, Shihab FS, Mulloy L, Henning AK, Gao J, Bartucci M, Holman J, First MR, OPTIMA Study Group.
    Transplantation; 2008 Jul 15; 86(1):88-95. PubMed ID: 18622283
    [Abstract] [Full Text] [Related]

  • 15. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S, He X, Yang L, Ma Y, Zhu X, Ju W, Huang J.
    Exp Clin Transplant; 2008 Jun 15; 6(2):113-7. PubMed ID: 18816237
    [Abstract] [Full Text] [Related]

  • 16. Monitoring peripheral blood CD4+ adenosine triphosphate activity in a liver transplant cohort: insight into the interplay between hepatitis C virus infection and cellular immunity.
    Mendler M, Kwok H, Franco E, Baron P, Weissman J, Ojogho O.
    Liver Transpl; 2008 Sep 15; 14(9):1313-22. PubMed ID: 18756485
    [Abstract] [Full Text] [Related]

  • 17. Factors influencing renal function after liver transplantation. Results from the MOST, an international observational study.
    Burra P, Senzolo M, Masier A, Prestele H, Jones R, Samuel D, Villamil F.
    Dig Liver Dis; 2009 May 15; 41(5):350-6. PubMed ID: 19046932
    [Abstract] [Full Text] [Related]

  • 18. Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial.
    Martin P, Busuttil RW, Goldstein RM, Crippin JS, Klintmalm GB, Fitzsimmons WE, Uleman C.
    Liver Transpl; 2004 Oct 15; 10(10):1258-62. PubMed ID: 15376310
    [Abstract] [Full Text] [Related]

  • 19. Incidence, risk factors, and outcome of chronic rejection during antiviral therapy for posttransplant recurrent hepatitis C.
    Fernández I, Ulloa E, Colina F, Abradelo M, Jiménez C, Gimeno A, Meneu JC, Lumbreras C, Solís-Herruzo JA, Moreno E.
    Liver Transpl; 2009 Aug 15; 15(8):948-55. PubMed ID: 19642125
    [Abstract] [Full Text] [Related]

  • 20. Preliminary results of immunosuppression with thymoglobuline pretreatment and hepatitis C virus recurrence in liver transplantation.
    De Ruvo N, Cucchetti A, Lauro A, Masetti M, Cautero N, Di Benedetto F, Dazzi A, Del Gaudio M, Ravaioli M, Zanello M, La Barba G, di Francesco F, Risaliti A, Ramacciato G, Pinna AD.
    Transplant Proc; 2005 Aug 15; 37(6):2607-8. PubMed ID: 16182760
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.